KENALOG-40
Kenalog-40 (triamcinolone acetonide) is an injectable corticosteroid indicated for intramuscular use when oral therapy is not feasible. It is utilized to manage a broad spectrum of severe, chronic, or acute conditions, including allergic, dermatologic, endocrine, gastrointestinal, hematologic, ophthalmic, renal, and nervous system disorders (such as acute exacerbations of multiple sclerosis). Additionally, it serves as palliative management for certain neoplastic diseases (leukemias and lymphomas) and as adjunctive therapy for tuberculous meningitis and trichinosis with myocardial or neurologic involvement.
How KENALOG-40 Works
Triamcinolone acetonide is a synthetic glucocorticoid with potent anti-inflammatory and immunomodulatory effects. It diffuses across cell membranes and binds with high affinity to specific cytoplasmic glucocorticoid receptors. This complex translocates to the nucleus, where it binds to DNA response elements to modulate gene transcription. This results in the inhibition of pro-inflammatory cytokine production, reduced synthesis of inflammatory mediators (such as prostaglandins and leukotrienes), suppression of polymorphonuclear leukocyte migration, and decreased capillary permeability. Unlike natural hydrocortisone, triamcinolone has potent glucocorticoid activity with minimal mineralocorticoid (salt-retaining) effects.
Details
- Status
- Prescription
- First Approved
- 1965-02-01
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
KENALOG-40 Approval History
What KENALOG-40 Treats
10 indicationsKENALOG-40 is approved for 10 conditions since its original approval in 1965. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Asthma
- Atopic Dermatitis
- Contact Dermatitis
- Drug Hypersensitivity
- Allergic Rhinitis
- Serum Sickness
- Transfusion Reaction
- Bullous Dermatitis Herpetiformis
Drugs Similar to KENALOG-40
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KENALOG-40 FDA Label Details
ProIndications & Usage
FDA Label (PDF)Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.